Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation

被引：10

作者：

Miyauchi, Shunsaku ^{[1
]}

Shien, Kazuhiko ^{[1
]}

Takeda, Tatsuaki ^{[2
]}

Araki, Kota ^{[1
]}

Nakata, Kentaro ^{[1
]}

Miura, Akihiro ^{[1
]}

Takahashi, Yuta ^{[1
]}

Kurihara, Eisuke ^{[1
]}

Ogoshi, Yusuke ^{[1
]}

Namba, Kei ^{[1
]}

Suzawa, Ken ^{[1
]}

Yamamoto, Hiromasa ^{[1
]}

Okazaki, Mikio ^{[1
]}

Soh, Junichi ^{[1
]}

Tomida, Shuta ^{[4
]}

Yamane, Masaomi ^{[1
]}

Sakaguchi, Masakiyo ^{[3
]}

Toyooka, Shinichi ^{[1
]}

机构：

[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Breast & Endocrinol Surg, Okayama, Japan

[2] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharm, Okayama, Japan

[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cell Biol, Okayama, Japan

[4] Okayama Univ Hosp, Ctr Comprehens Genom Med, Okayama, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 05期

关键词：

Pan-RAF inhibitor; LY3009120; non-small cell lung cancer; BRAF mutation; DABRAFENIB PLUS TRAMETINIB; PRECLINICAL MODELS; OPEN-LABEL; FEATURES; RESISTANCE;

D O I：

10.21873/anticanres.14237

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The therapeutic strategy for patients with non-small-cell lung cancer (NSCLC) harboring the BRAF non-V600E mutation has not been established. LY3009120, a newly discovered pan-RAF inhibitor, has shown strong antitumor effects in cancers with various BRAF genotypes. This study investigated the antitumor effects of LY3009120 in NSCLC cells harboring the BRAF non-V600E mutation. Materials and Methods: We examined the antitumor effects of LY3009120 by MTS assay and flow cytometry. We analyzed the expression status of proteins by western blot. The mouse xenograft models were used for the in vivo experiments. Results: LY3009120 suppressed BRAF-related downstream pathway molecules and induced cleavage of poly ADP-ribose polymerase in all examined NSCLC cell lines. LY3009120 also inhibited in vivo tumor growth in NSCLC cells harboring the BRAF non-V600E mutation. Conclusion: LY3009120 is a potent therapeutic agent for patients with BRAF non-V600E mutant NSCLC.

引用

页码：2667 / 2673

页数：7

共 50 条

[21] pan-RAF抑制剂LY3009120对分化型甲状腺癌细胞增殖、侵袭和迁移的影响及可能机制
樊新龙
郭囡
高鑫
杨骁
石岗
赵月皎
现代肿瘤医学, 2018, 26 (22) : 3554 - 3557
[22] DAY101, a potent pan-RAF inhibitor with activity in preclinical models harboring MAPK pathway alterations beyond BRAF V600E mutation.
Venetsanakos, Eleni
Preigh, Mike
Hou, Jeannie
Cox, Michael C.
Bender, Jeremy
Blackman, Sam C.
CANCER RESEARCH, 2021, 81 (13)
[23] Anti-cancer effects of a novel Pan-RAF inhibitor in a hepatocellular carcinoma cell line
Wang, Wei
Xu, Bo
Li, Qixiang
Jiang, Dechun
Yan, Suying
MOLECULAR MEDICINE REPORTS, 2018, 17 (04) : 6185 - 6193
[24] RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
S-H Chen
X Gong
Y Zhang
R D Van Horn
T Yin
L Huber
T F Burke
J Manro
P W Iversen
W Wu
S V Bhagwat
R P Beckmann
R V Tiu
S G Buchanan
S-B Peng
Oncogene, 2018, 37 : 821 - 832
[25] RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
Chen, S-H
Gong, X.
Zhang, Y.
Van Horn, R. D.
Yin, T.
Huber, L.
Burke, T. F.
Manro, J.
Iversen, P. W.
Wu, W.
Bhagwat, S. V.
Beckmann, R. P.
Tiu, R. V.
Buchanan, S. G.
Peng, S-B
ONCOGENE, 2018, 37 (06) : 821 - 832
[26] Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells
Henry, James R.
Kaufman, Michael D.
Peng, Sheng-Bin
Ahn, Yu Mi
Caldwell, Timothy M.
Vogeti, Lakshminarayana
Telikepalli, Hanumaiah
Lu, Wei-Ping
Hood, Molly M.
Rutkoski, Thomas J.
Smith, Bryan D.
Vogeti, Subha
Miller, David
Wise, Scott C.
Chun, Lawrence
Zhang, Xiaoyi
Zhang, Youyan
Kays, Lisa
Hipskind, Philip A.
Wrobleski, Aaron D.
Lobb, Karen L.
Clay, Julia M.
Cohen, Jeffrey D.
Walgren, Jennie L.
McCann, Denis
Patel, Phenil
Clawson, David K.
Guo, Sherry
Manglicmot, Danalyn
Groshong, Chris
Logan, Cheyenne
Starling, James J.
Flynn, Daniel L.
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (10) : 4165 - 4179
[27] Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells
Park, Siyeon
Kim, Tae Min
Cho, Sung-Yup
Kim, Soyeon
Oh, Yumi
Kim, Miso
Keam, Bhumsuk
Kim, Dong-Wan
Heo, Dae Seog
CANCER LETTERS, 2020, 495 : 135 - 144
[28] Combination of an ERK1/2 inhibitor (LY3214996) with pan-RAF inhibitor enhances anti-tumor activity in KRAS mutant colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)
Wu, Wenjuan
Bhagwat, Shripad
Kindler, Lisa
McMillen, William
Joseph, Sajan
Buchanan, Sean
Reinhard, Christoph
Tiu, Ramon V.
Peng, Sheng-Bin
CANCER RESEARCH, 2019, 79 (13)
[29] Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion
Watanabe, Junko
Furuya, Naoki
Fujiwara, Yutaka
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : E66 - E69
[30] Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations
Yamada, T.
Amann, J.
Tanimoto, A.
Taniguchi, H.
Shukuya, T.
Yano, S.
Takayama, K.
Carbone, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2273 - S2273

← 1 2 3 4 5 →